During the February webinar (~48m), Jon Pilcher was asked about the possibility of combining the four disorders into one Phase 3 basket trial.
His answer was that it was unlikely – not only do the different disorders have slightly different endpoints, but also the FDA is going to want efficacy shown in each different disorder anyway.
- Forums
- ASX - By Stock
- Ann: 2023 Annual Report to shareholders
During the February webinar (~48m), Jon Pilcher was asked about...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.66 |
Change
-0.090(0.65%) |
Mkt cap ! $1.753B |
Open | High | Low | Value | Volume |
$13.85 | $14.08 | $13.46 | $4.001M | 292.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 635 | $13.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.67 | 200 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 1804 | 13.690 |
7 | 664 | 13.680 |
8 | 842 | 13.670 |
6 | 580 | 13.660 |
6 | 893 | 13.650 |
Price($) | Vol. | No. |
---|---|---|
13.700 | 1075 | 10 |
13.710 | 489 | 6 |
13.720 | 469 | 4 |
13.730 | 438 | 4 |
13.740 | 948 | 4 |
Last trade - 13.53pm 10/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |